The widespread distribution of TRH in the cerebral cortex, hypothalamus, and spinal cord have led to the suggestion that it may act as a neurotransmitter, but in man there is no good evidence to support this view. It has no effect on the contingent negative variation, a sensitive indicator of the brain activity which results from other agents such as diazepam and nicotine (Ashton et al., 1976) .
Thyrotrophin-releasing hormone (TRH), a tripeptide with the formula pyroglutamyl histidylprolinamide, was first isolated by Schally and his coworkers in 1969 and now has an established role in clinical endocrine practice. When given to animals in pharmacological doses it has a variety of neurotropic actions. These include arousal; increased respiration, muscle tone, and body temperature; and emotional behaviour. It also increases the LD5o of barbiturates. Side effects in man are minor and transient with the 200-,ug intravenous dose used in the standard TRH test. They include nausea, a desire to micturate, flushing, dizziness, an unusual taste, and an increase in the pulse rate. No adverse effects on the liver, kidney, or bone marrow have been reported.
The widespread distribution of TRH in the cerebral cortex, hypothalamus, and spinal cord have led to the suggestion that it may act as a neurotransmitter, but in man there is no good evidence to support this view. It has no effect on the contingent negative variation, a sensitive indicator of the brain activity which results from other agents such as diazepam and nicotine (Ashton et al., 1976) .
Factors affecting TRH test in normal subjects
The peak TSH response to an intravenous 200-,ug bolus of TRH occurs between 20 and 30 minutes, and 20 minutes has usually been chosen as the peak for the standard TRH test. TSH levels return towards basal after 60 minutes, but it is unnecessary to take a 60-minute specimen when investigating a patient with thyroid disease. The TSH released by TRH acts on the normal thyroid to release tri-iodothyronine (T3), with a peak level at about 3 hours after injection, and thyroxine (T4), with a peak level at 4-6 hours after injection. Measurements of T3 and T4 at these intervals can be used to monitor the response of the thyroid. Women, especially in the premenstrual phase of the cycle, show a greater response than men. The TSH response to TRH has been reported to fall with age. The response is greater at night, which would be expected because of the nocturnal rise of TSH levels.
A variety of drugs affect the TSH response to 
OPHTHALMIC GRAVES S DISEASE
Such patients have the eye signs of Graves's disease yet are not hyperthyroid and give no past history of hyperthyroidism. In some the pattern of the eye signs is diagnostic of Graves's disease, but in others, especially those with unilateral proptosis, an orbital tumour must be excluded. In those cases the finding of an abnormal TRH test indicating a minor thyroid abnormality is helpful in diagnosis. Any pattern of TSH response to TRH can be observed in ophthalmic Graves's disease from exaggerated to normal or impaired to absent, depending on the level of thyroid function ranging from overt hypothyroidism to subclinical hyperthyroidism.
TRH test in hypothalamic-pituitary disease
Patients with hypothalamic-pituitary disease can be investigated with the TRH test. A normal TRH test usually correlates with normal circulating thyroid hormone levels, but occasional patients with hypothyroidism due to hypothalamic-pituitary disease also have a normal or exaggerated response. Some of them fail to show any T3 or T4 response to TRH despite a release of TSH detected by radioimmunoassay. But by cytochemical bioassay the results are different and only small amounts of biologically active TSH are detected.
Patients with acromegaly often fail to respond to TRH, even when they are clinically and biochemically euthyroid. Suppression of the TRH test by an autonomous nodular goitre is often responsible for this finding. Patients with hypothalamic disease may show a normal peak response to TRH even when hypothyroid but the response is characteristically a delayed one, the level at 60 minutes being greater than at 20 minutes.
Neuroregulation of TSH secretion
This is poorly understood, although the finding that the TSH response to TRH is reduced after administration of certain neuroactive agents has thrown some light on the matter. Thus both continuous administration of levodopa and acute dopamine infusion inhibit the TSH response to TRH, suggesting an overall inhibitory dopaminergic control of TSH secretion.
Growth hormone release-inhibiting hormone (GHR-IH) (somatostatin) also suppresses TRHinduced TSH release. A physiological role for GH-R-IH in TSH regulation in man has been inferred from the rise in basal TSH levels that occurs after administration of an antiserum to somatostatin in animals.
Therapeutic applications of TRH
As yet no firm therapeutic applications have been found for TRH. It has no place in the treatment of depression. An absence of response to TRH after a course of antithyroid drugs may forecast relapse before a rise in serum T3 or T4, but in general an absent respeonse to TRH at the end of a course of antithyroid drugs has not been found to be a good predictor of which patients are liable to relapse. The TRH test is of no value in assessing thyroid function during antithyroid treatment. TRH may be used to enhance release of endogenous TSH in patients with thyroid cancer instead of giving bovine TSH, after the withdrawal of thyroid medication, to reduce the duration of hypothyroidism and possibly enhance radioiodine uptake by tumour tissue. TRH can be used to treat hypothalamic hypothyroidism, but thyroxine is cheaper and more convenient. Prolactin levels can be raised post-partum by oral TRH, but there is no enhancement of milk production.
